4D Molecular Therapeutics Inc. - news published 225 - readings 7.858

BACK
4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc.

4DMT Announces First Patients Enrolled in 4FRONT 1 Phase 3 Clinical Trial Evaluating 4D 150 in Wet AMD

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer 4D Molecular Therapeutics Inc. published this content on March 10, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 10, 2025 at 12:07:31.971 .

Continue reading
10.03.2025
4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc.

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)

Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes included elsewhere in this Annual Report on Form 10-K (this "report"). This discussion and analysis and other part ...

Continue reading
02.03.2025
4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc.

Post-Effective Amendment to Automatic Shelf Registration Statement (Form POSASR)

Table of Contents As filed with the Securities and Exchange Commission on February 28, 2025 Registration No. 333-276872 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 4D Molecular Therapeutics, Inc. (Exact name of registrant as specified in its charter) D ...

Continue reading
28.02.2025
4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc.

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer 4D Molecular Therapeutics Inc. published this content on February 28, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 28, 2025 at 23:07:28.242 .

Continue reading
28.02.2025
4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc.

Initial Registration Statement for Employee Benefit Plan (Form S-8)

As filed with the Securities and Exchange Commission on February 28, 2025 Registration No. 333-    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 4D Molecular Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3506994 (State or other jurisdiction o ...

Continue reading
28.02.2025